- Conditions: Colorectal Cancer; Dysgeusia; Oral Complications of Chemotherapy
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Biological: bovine lactoferrin
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012 - Conditions: Gynecologic Malignancy; Abdominal Surgery by Laparotomy; Pain; Psychological Distress; Lung Function; Surgical Complications
Interventions: Other: Mindful Movement and Breathing program; Other: Questionnaire administration; Procedure: The Observer Mobility Scale; Procedure: Volumetric Incentive Spirometry
Sponsors: Wake Forest University; Wake Forest University
Not yet recruiting - verified May 2012 - Conditions: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Interventions: Drug: Memantine HCl; Drug: Memantine HCl; Drug: Placebo capsules
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified May 2012 - Conditions: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Intervention: Drug: Memantine HCl
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified May 2012 - Conditions: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Intervention: Drug: Memantine HCl
Sponsors: Forest Laboratories; Forest Laboratories
Not yet recruiting - verified May 2012 - Conditions: Fatigue; Nausea and Vomiting; Pain; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage I-IVB Colon Cancer; Stage I-IVB Rectal Cancer
Interventions: Procedure: Yoga therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: assessment of therapy complications; Procedure: management of therapy complications; Other: educational intervention
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified May 2012 - Condition: Mesothelioma
Intervention:
Sponsors: Wake Forest University; Wake Forest University; University of Pennsylvania; Mayo Clinic; New York University School of Medicine; Johns Hopkins University; Mount Sinai School of Medicine; Memorial Sloan-Kettering Cancer Center; Mesothelioma Applied Research Foundation, Inc.
Recruiting - verified May 2012 - Condition: Distal Radius Fracture
Interventions: Procedure: Open Reduction and Internal Fixation; Procedure: External Fixation; Procedure: Percutaneous Pinning; Procedure: Closed Reduction and casting
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Meningioma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Tumor; Adult Craniopharyngioma; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Myxopapillary Ependymoma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pilocytic Astrocytoma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Pineocytoma; Adult Subependymal Giant Cell Astrocytoma; Adult Subependymoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET); Meningeal Melanocytoma; Nonmalignant Neoplasm; Recurrent Adult Brain Tumor; Tumors Metastatic to Brain
Interventions: Drug: pioglitazone hydrochloride; Other: laboratory biomarker analysis; Radiation: external beam radiation therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity
Interventions: Radiation: intensity-modulated radiation therapy; Procedure: quality-of-life assessment; Drug: erlotinib hydrochloride; Drug: pemetrexed disodium; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: immunohistochemistry staining method; Genetic: protein expression analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2010 - Conditions: Squamous Cell Carcinoma of the Skin; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Squamous Cell Carcinoma of the Oropharynx; Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Squamous Cell Carcinoma of the Oropharynx; Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage II Verrucous Carcinoma of the Oral Cavity
Interventions: Drug: erlotinib hydrochloride; Procedure: therapeutic conventional surgery
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009 - Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide; Drug: Formoterol Fumarate; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories; Almirall, S.A.
Enrolling by invitation - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified April 2012 - Condition: COPD
Interventions: Drug: roflumilast; Drug: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified April 2012 - Condition: Bacterial Pneumonia
Interventions: Drug: IV meropenem; parenteral aminoglycoside; Drug: I.V. Meropenem
Sponsors: University of Florida; University of Florida
Not yet recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Aclidinium/Formoterol; Drug: Formoterol
Sponsors: Forest Laboratories; Forest Laboratories; Almirall, S.A.
Active, not recruiting - verified March 2012 - Conditions: Bone Cancer; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Metastatic Osteosarcoma; Ovarian Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Osteosarcoma; Recurrent Uterine Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage III Uterine Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Uterine Sarcoma
Interventions: Drug: therapeutic angiotensin-(1-7); Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Active, not recruiting - verified March 2012 - Conditions: Anxiety Disorder; Fatigue; Malignant Neoplasm; Nausea and Vomiting; Pain
Interventions: Other: questionnaire administration; Procedure: therapeutic touch; Behavioral: management of therapy complications; Behavioral: management of therapy complications; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Mild Cognitive Impairment; Cognitive Disorders
Intervention: Behavioral: 5-month aerobic exercise intervention
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified March 2012 - Conditions: Cardiovascular Disease; Obesity; Physical Disability
Intervention: Behavioral: Weight Loss and Exercise
Sponsors: Wake Forest University; Wake Forest University
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Borage and Echium Seed Oils; Drug: Corn oil pills
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Wake Forest University
Not yet recruiting - verified March 2012 - Conditions: Prehypertension; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol; Drug: Placebo
Sponsors: University of Colorado, Boulder; University of Colorado, Boulder; Forest Laboratories
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Conditions: Extrahepatic Bile Duct Cancer; Nausea; Vomiting; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: aprepitant; Drug: gemcitabine hydrochloride; Drug: capecitabine; Drug: fluorouracil; Procedure: radiation therapy; Other: questionnaire administration; Procedure: quality-of-life assessment; Procedure: nausea and vomiting therapy; Procedure: management of therapy complications
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI); Merck
Active, not recruiting - verified February 2012 - Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach; Squamous Cell Carcinoma of the Esophagus; Stage II Esophageal Cancer; Stage II Gastric Cancer; Stage III Esophageal Cancer; Stage III Gastric Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: oxaliplatin; Drug: fluorouracil; Radiation: radiation therapy; Procedure: conventional surgery; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Procedure: computed tomography; Procedure: laboratory biomarker analysis; Genetic: gene expression analysis; Radiation: fludeoxyglucose F 18
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Active, not recruiting - verified March 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: therapeutic angiotensin-(1-7); Other: pharmacological study; Other: laboratory biomarker analysis; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Active, not recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin; Biological: pegfilgrastim; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: genetic linkage analysis; Drug: docetaxel
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI); OSI Pharmaceuticals
Active, not recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Breast Cancer; Cancer Survivor; Colorectal Cancer; Lung Cancer; Prostate Cancer; Tobacco Use Disorder
Interventions: Drug: memantine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012 - Condition: Pain
Intervention: Device: Remote Ischemic Preconditioning, Capsaicin, UV-B
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Not yet recruiting - verified February 2012 - Condition: Physical Activity
Interventions: Behavioral: Prosocial Behavior Physical Activity (PBPA); Other: Healthy Aging (HA)
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Not yet recruiting - verified February 2012 - Conditions: Asthma; Atopy
Interventions: Drug: fluticasone; Drug: Placebo
Sponsors: Milton S. Hershey Medical Center; dave mauger; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified February 2012 - Conditions: Calculi; Stenosis of Bile Duct
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified February 2012 - Condition: Severe Aortic Stenosis
Intervention: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified April 2012 - Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: quality-of-life assessment; Other: counseling intervention; Behavioral: exercise intervention; Other: educational intervention; Procedure: standard follow-up care
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Malignant Neoplasm
Interventions: Drug: placebo administration; Drug: EMLA; Drug: propofol; Drug: fentanyl citrate
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Pneumonia, Bacterial; Community-acquired
Interventions: Drug: Ceftaroline; Drug: Levofloxacin
Sponsors: Michigan State University; Gary E. Stein, Pharm.D.; Forest Laboratories
Recruiting - verified February 2012 - Condition: Obesity
Intervention: Procedure: Endoscopy
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified February 2012 - Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: CPI-613
Sponsors: Cornerstone Pharmaceuticals, Inc.; Cornerstone Pharmaceuticals, Inc.
Not yet recruiting - verified February 2012 - Condition: Jaundice
Interventions: Procedure: EUS-FNA first, followed by CRCP with bilinary stenting; Procedure: ERCP with stent placement, followed by EUS-FNA
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified January 2012 - Condition: Healthy
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified January 2012 - Conditions: Stage 1 Hypertension; Stage 2 Hypertension
Interventions: Drug: Nebivolol and Valsartan 1; Drug: Nebivolol and Valsartan 2; Drug: Nebivolol and Valsartan 3; Drug: Nebivolol 1; Drug: Nebivolol 2; Drug: Valsartan 1; Drug: Valsartan 2; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: atenolol; Drug: placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Forest Laboratories
Recruiting - verified January 2012 - Condition: Acne Vulgaris
Interventions: Drug: Adapalene + benzoyl peroxide samples; Drug: Adapalene + benzoyl peroxide from standard tube
Sponsors: Wake Forest University; Wake Forest University; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Condition: Postoperative Nausea and Vomiting
Interventions: Drug: Ondansetron; Drug: Vestipitant
Sponsors: Octagon Research Solutions, Inc.; Octagon Research Solutions, Inc.
Recruiting - verified May 2012 - Condition: Acute Respiratory Distress Syndrome
Interventions: Drug: Aspirin; Drug: Lactose powder
Sponsors: Mayo Clinic; Ognjen Gajic; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Vanderbilt University
Not yet recruiting - verified January 2012 - Condition: Heart Failure
Interventions: Behavioral: Usual care; Behavioral: Rehabilitation intervention
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified January 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Papulopustular Rosacea (PPR)
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Huntington's Disease
Intervention: Drug: SEN0014196
Sponsors: Siena Biotech S.p.A.; Siena Biotech S.p.A.
Recruiting - verified March 2012 - Condition: Critical Limb Ischemia
Interventions: Biological: Ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2012 - Condition: Knee Osteoarthritis
Interventions: Behavioral: High Intensity Strength Training; Behavioral: Low Intensity Strength Training; Behavioral: Attention Control
Sponsors: Wake Forest University; Wake Forest University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting - verified December 2011 - Conditions: Knee Osteoarthritis; Degenerative Joint Disease; Chronic Pain
Interventions: Drug: Milnacipran; Drug: Placebo
Sponsors: Rehabilitation Institute of Chicago; Dr. Norman Harden; Forest Laboratories
Recruiting - verified January 2012 - Condition: Hypertension
Interventions: Drug: Metoprolol succinate; Drug: Nebivolol; Drug: Hydrochlorothiazide; Drug: DEFINITY®; Procedure: Non-invasive measurement of Cardiac Output (CO); Procedure: Flow mediated vasodilation; Procedure: Endothelial cell collection; Procedure: Microvascular perfusion assessment using Definity
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Forest Laboratories
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: GK1-399 (formerly TTP399); Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone; Drug: Vilazodone; Drug: Citalopram
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Placebo; Drug: Vilazodone
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified February 2012 - Condition: Meshed Split-Thickness Skin Graft Scar
Interventions: Device: ReCell; Other: Treatment with dermabrasion
Sponsors: Avita Medical Americas, LLC; Avita Medical Americas, LLC
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: AIN457 (secukinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: cariprazine; Drug: cariprazine; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Conditions: Hypertension; Chronic Kidney Disease
Intervention:
Sponsors: University of Utah; University of Utah; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Sponsors: Wake Forest University; Wake Forest University; Medicis Pharmaceutical Corporation
Recruiting - verified November 2011 - Conditions: Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Implantable Cardioverter Defibrillator
Interventions: Drug: Azimilide Dihydrochloride; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified May 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: Milnacipran; Drug: Milnacipran; Drug: Milnacipran; Drug: Placebo
Sponsors: University of North Carolina, Chapel Hill; Spencer Dorn, MD, MPH; Forest Laboratories
Recruiting - verified January 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide; Drug: Placebo
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Recruiting - verified February 2012 - Conditions: Anxiety Disorder; Breast Cancer; Cancer Survivor; Cognitive/Functional Effects; Depression; Fatigue; Sleep Disorders
Interventions: Drug: donepezil hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011 - Condition: Open Fracture
Intervention:
Sponsors: Major Extremity Trauma Research Consortium; Major Extremity Trauma Research Consortium; Department of Defense
Recruiting - verified December 2011 - Condition: Interstitial Cystitis
Interventions: Drug: Lidocaine Releasing Intravesical System - LiRIS®; Other: LiRIS Placebo; Procedure: Sham
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011 - Condition: Hypertension
Interventions: Drug: Metoprolol succinate; Drug: Nebivolol; Procedure: Forearm blood flow; Procedure: Microneurography; Procedure: Rhythmic handgrip exercise; Procedure: Lower body negative pressure; Drug: Angiotensin II
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Forest Laboratories
Recruiting - verified April 2012 - Condition: Rotator Cuff Tear
Intervention:
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified February 2012 - Conditions: Adult Acute Lymphoblastic Leukemia; Adult Acute Myeloid Leukemia; Adult Burkitt Lymphoma; Adult Diffuse Large Cell Lymphoma; Adult Diffuse Mixed Cell Lymphoma; Adult Diffuse Small Cleaved Cell Lymphoma; Adult Hodgkin Lymphoma; Adult Immunoblastic Large Cell Lymphoma; Adult Lymphoblastic Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Breast Cancer; Chronic Eosinophilic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Cutaneous T-cell Non-Hodgkin Lymphoma; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Malignant Testicular Germ Cell Tumor; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Multiple Myeloma; Mycosis Fungoides/Sezary Syndrome; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neutropenia; Nodal Marginal Zone B-cell Lymphoma; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Plasma Cell Neoplasm; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Primary Myelofibrosis; Prolymphocytic Leukemia; Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma
Intervention: Drug: cefepime hydrochloride
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Malignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Central Nervous System Neoplasm
Interventions: Biological: trivalent influenza vaccine; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Conditions: Cognitive/Functional Effects; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: ultrasound imaging; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: magnetic resonance imaging
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Limited Stage Small Cell Lung Cancer; Recurrent Small Cell Lung Cancer; Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Tobacco Use Disorder
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Other: counseling intervention; Other: internet-based intervention; Behavioral: telephone-based intervention; Other: educational intervention; Drug: nicotine replacement therapy; Other: educational intervention
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Active, not recruiting - verified April 2012 - Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Tiotropium; Drug: Placebo
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Completed - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide; Drug: Placebo; Drug: Formoterol Fumarate
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Recruiting - verified October 2011 - Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: AFX-2; Drug: AFX-2; Drug: AFX-2; Drug: AFX-2; Drug: AFX-2
Sponsors: Afexa Life Sciences Inc; Afexa Life Sciences Inc
Withdrawn - verified January 2012 - Conditions: Peripheral Artery Disease; Hypertension
Interventions: Drug: nebivolol; Drug: Metoprolol succinate
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Forest Laboratories
Recruiting - verified December 2011 - Condition: Vascular Function
Interventions: Procedure: Forearm Vascular Study; Procedure: Badimon Chamber
Sponsors: University of Edinburgh; University of Edinburgh; Umeå University; NHS Lothian
Recruiting - verified October 2011 - Condition: Actinic Keratosis
Interventions: Other: AKRQ questionnaire; Other: Skindex-16, DLQI, Skin Health Calculator
Sponsors: Wake Forest University; Wake Forest University
Active, not recruiting - verified February 2012 - Conditions: COPD; COPD Exacerbation; Lung Diseases; Respiratory Disorders; Pulmonary Disease; Chronic Obstructive Lung Diseases; Chronic Obstructive Airway Disease
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Biological: MEDI8968 SC for 12 months; Biological: Placebo SC for 12 months
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: Zoll Medical Corporation; Zoll Medical Corporation; University of California, San Francisco
Recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide; Drug: Formoterol Fumarate; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Almirall, S.A.
Recruiting - verified March 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Formoterol Fumarate
Sponsors: Forest Laboratories; Forest Laboratories; Almirall, S.A.
Active, not recruiting - verified January 2012 - Condition: Healthy
Interventions: Drug: Ceftaroline; Drug: Ceftaroline
Sponsors: AstraZeneca; AstraZeneca; Forest Laboratories
Completed - verified February 2012 - Conditions: Transplant; Failure, Kidney; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol succinate
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Forest Laboratories; Lahey Clinic
Recruiting - verified February 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: Cobicistat; Drug: Darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2011 - Condition: Asthma
Interventions: Drug: Zithromax; Drug: Placebo
Sponsors: Imperial College London; Imperial College London; National Institute for Health Research, United Kingdom
Not yet recruiting - verified September 2011 - Condition: Psoriasis
Interventions: Behavioral: Standard nurse education; Behavioral: Additional nurse education
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified September 2011 - Conditions: Sepsis; Acute Lung Injury; Acute Respiratory Distress Syndrome
Interventions: Biological: TNX-832; Drug: Placebo
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; Genentech; Tanox
Completed - verified September 2011 - Conditions: Skin Wound; Burn Wounds; Infection Related Wound; Trauma-related Wound
Intervention: Biological: StrataGraft Skin Tissue
Sponsors: Stratatech; Stratatech
Recruiting - verified April 2012 - Conditions: Lung Cancer; Tobacco Use Disorder
Interventions: Drug: nicotine patch; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified September 2011 - Condition: Central Nervous System
Intervention:
Sponsors: Wake Forest University; Wake Forest University
Completed - verified March 2012 - Conditions: Major Depressive Disorder; Attention-deficit Hyperactivity Disorder (ADHD)
Intervention:
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified September 2011 - Condition: Stress
Interventions: Other: Interpersonal Mindful Compassion with Touch; Other: Reading while extending loving kindness
Sponsors: Wake Forest University; Wake Forest University
Completed - verified September 2011 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: LAS100977; Drug: LAS100977; Drug: LAS100977; Drug: LAS100977; Drug: Reference; Drug: Placebo
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Completed - verified January 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: LAS100977; Drug: LAS100977; Drug: LAS100977; Drug: LAS100977; Drug: Reference; Drug: Placebo
Sponsors: Almirall, S.A.; Almirall, S.A.; Forest Laboratories
Completed - verified January 2012 - Condition: Severe Open Fractures of the Tibia (Shin) Bone
Interventions: Procedure: Surgery with an external ring fixator; Procedure: Definitive fixation with a locked IM nail or plate
Sponsors: Major Extremity Trauma Research Consortium; Major Extremity Trauma Research Consortium; Department of Defense
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: bortezomib; Drug: decitabine
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hypertension
Intervention: Drug: Nebivolol, Valsartan and Hydrochlorothiazide
Sponsors: Forest Laboratories; Forest Laboratories
Active, not recruiting - verified February 2012 - Condition: Hypertension
Interventions: Drug: Nebivolol; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Active, not recruiting - verified February 2012 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: Cariprazine; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2012 - Conditions: Vitamin D Deficiency; Accidental Falls
Interventions: Dietary Supplement: Vitamin D3; Dietary Supplement: Vitamin E
Sponsors: Wake Forest University; Wake Forest University
Enrolling by invitation - verified February 2011 - Conditions: Breast Cancer; Cognitive/Functional Effects; Depression; Fatigue; Pain; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Skin Reactions Secondary to Radiation Therapy
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy; Radiation: breast irradiation; Radiation: external beam radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Heart Failure With Preserved Ejection Fraction; Heart Failure, Congestive
Interventions: Drug: Enalapril; Drug: placebo
Sponsors: Wake Forest University; Wake Forest University
Completed - verified August 2011 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Pain; Impairment, Light Touch Sensation
Interventions: Device: pulsed ultrasound device with lidocaine; Other: off device; Device: continuous ultrasound device with lidocaine
Sponsors: Shiraz University of Medical Sciences; Shiraz University of Medical Sciences
Completed - verified March 2011 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified March 2012 - Condition: Asthma
Intervention: Drug: Tralokinumab
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012 - Conditions: Focal Neuropathies; Carpal Tunnel Syndrome; Cubital Tunnel Syndrome; Median Neuropathy; Ulnar Neuropathy; Peroneal Neuropathy; Radial Neuropathy; Sciatic Neuropathy; Tibial Neuropathy
Intervention:
Sponsors: Wake Forest University; Wake Forest University
Not yet recruiting - verified July 2011 - Condition: Chronic Pain
Intervention: Other: Observational
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified February 2012 - Conditions: Diabetes; Weight Loss; Physical Function; Cognitive Function
Interventions: Behavioral: Lifestyle intervention; Behavioral: Diabetes Support Education
Sponsors: Wake Forest University; Wake Forest University; Pennington Biomedical Research Center; University of Colorado, Denver; University of Tennessee; University of Pittsburgh
Recruiting - verified September 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Memantine
Sponsors: Mclean Hospital; Mclean Hospital; Cambridge Health Alliance; Harvard University
Active, not recruiting - verified May 2012 - Conditions: Effect of Lexapro(Escitalopram)on Learning; Health Controls
Intervention: Drug: Escitalopram
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Forest Laboratories
Completed - verified July 2011 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified April 2012 - Condition: Atopic Dermatitis
Interventions: Behavioral: Weekly Internet survey; Drug: Topical Triamcinolone
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified June 2011 - Condition: Catheter Complications
Intervention:
Sponsors: 3M; 3M
Enrolling by invitation - verified July 2011 - Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Drug: BIBF 1120
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Boehringer Ingelheim Pharmaceuticals; Wake Forest University Baptist Medical Center; Dartmouth-Hitchcock Medical Center; University of Virginia; Massachusetts General Hospital
Not yet recruiting - verified December 2011 - Condition: Schizophrenia
Interventions: Drug: Cariprazine; Drug: Risperidone/Moxifloxacin; Drug: Risperidone/Moxifloxacin
Sponsors: Forest Laboratories; Forest Laboratories
Completed - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Levomilnacipran SR; Drug: Levomilnacipran SR; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Completed - verified April 2012 - Conditions: Cognitive/Functional Effects; Metastatic Cancer; Neurotoxicity; Radiation Toxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: stereotactic radiosurgery; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pain
Interventions: Device: Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1); Device: Sham RIPC
Sponsors: Wake Forest University Baptist Medical Center; Wake Forest University Baptist Medical Center
Recruiting - verified February 2012 - Condition: Major Depressive Disorder
Interventions: Device: NEST-1 (NeoSync EEG Synchronized TMS); Device: SHAM
Sponsors: NeoSync, Inc.; NeoSync, Inc.
Recruiting - verified May 2012 - Conditions: Prehypertension; Hypertension
Interventions: Drug: Nebivolol; Drug: Metoprolol; Drug: Placebo
Sponsors: University of Colorado, Boulder; University of Colorado, Boulder; Forest Laboratories
Recruiting - verified May 2012 - Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: TBI; Major Depression; Other Psychiatric Disorders
Intervention: Drug: Escitalopram
Sponsors: Johns Hopkins University; Johns Hopkins University; Forest Laboratories
Recruiting - verified February 2009
 |
Forest Laboratories - Database of Clinical Trials by Pharmaceutical Companies |
